Epigenetic mechanisms in breast cancer therapy and resistance

The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this pathway represent the main treatment modality. Endocrine therapy has proven successful in the treatment of hormone-responsive breast cancer since its early adoption in the 1940s as an ablative therapy. Unfor...

Full description

Saved in:
Bibliographic Details
Published in:Nature communications 2021-03, Vol.12 (1), p.1786-1786, Article 1786
Main Authors: Garcia-Martinez, Liliana, Zhang, Yusheng, Nakata, Yuichiro, Chan, Ho Lam, Morey, Lluis
Format: Article
Language:English
Subjects:
631/67/1347
692/699/2743
Ablation
Antineoplastic Agents, Hormonal - therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Cancer therapies
Chromatin
Deregulation
Disease resistance
Drug Resistance, Neoplasm - genetics
Endocrine therapy
Epigenesis, Genetic
Epigenetics
Epigenomics - methods
Estrogen receptors
Estrogens
Female
Gene Expression Regulation, Neoplastic
Health services
Humanities and Social Sciences
Humans
multidisciplinary
Neoplasm Recurrence, Local
Perspective
Phenotypes
Receptors, Estrogen - metabolism
Resistance factors
Science
Science (multidisciplinary)
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this pathway represent the main treatment modality. Endocrine therapy has proven successful in the treatment of hormone-responsive breast cancer since its early adoption in the 1940s as an ablative therapy. Unfortunately, therapeutic resistance arises, leading to disease recurrence and relapse. Recent studies increased our understanding in how changes to the chromatin landscape and deregulation of epigenetic factors orchestrate the resistant phenotype. Here, we will discuss how the epigenome is an integral determinant in hormone therapy response and why epigenetic factors are promising targets for overcoming clinical resistance. Endocrine therapy has been the mainstay for hormone responsive breast cancer treatment. Here, Garcia-Martinez and colleagues discuss epigenetic mechanisms regulating ER + breast cancer and endocrine therapy resistance, and highlight approaches to rewire the cancer epigenome to improve targeted therapies for this cancer.
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-021-22024-3